271 related articles for article (PubMed ID: 31201554)
1. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
De Marino S; Festa C; Sepe V; Zampella A
Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
[TBL] [Abstract][Full Text] [Related]
2. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
[TBL] [Abstract][Full Text] [Related]
3. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
4. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
[TBL] [Abstract][Full Text] [Related]
5. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
6. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1.
Di Leva FS; Festa C; Carino A; De Marino S; Marchianò S; Di Marino D; Finamore C; Monti MC; Zampella A; Fiorucci S; Limongelli V
Sci Rep; 2019 Feb; 9(1):2504. PubMed ID: 30792450
[TBL] [Abstract][Full Text] [Related]
8. The Pharmacology of Bile Acids and Their Receptors.
Fiorucci S; Distrutti E
Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
[TBL] [Abstract][Full Text] [Related]
9. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists.
Sepe V; Festa C; Renga B; Carino A; Cipriani S; Finamore C; Masullo D; Del Gaudio F; Monti MC; Fiorucci S; Zampella A
Sci Rep; 2016 Jan; 6():19008. PubMed ID: 26740187
[TBL] [Abstract][Full Text] [Related]
10. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
Fiorucci S; Distrutti E
Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
[TBL] [Abstract][Full Text] [Related]
11. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
[TBL] [Abstract][Full Text] [Related]
13. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
Di Leva FS; Di Marino D; Limongelli V
Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
[TBL] [Abstract][Full Text] [Related]
14. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
15. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders.
Fiorucci S; Zampella A; Distrutti E
Curr Top Med Chem; 2012; 12(6):605-24. PubMed ID: 22242859
[TBL] [Abstract][Full Text] [Related]
16. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
18. The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy.
Carino A; Marchianò S; Biagioli M; Scarpelli P; Bordoni M; Di Giorgio C; Roselli R; Fiorucci C; Monti MC; Distrutti E; Zampella A; Fiorucci S
FASEB J; 2021 Jan; 35(1):e21271. PubMed ID: 33368684
[TBL] [Abstract][Full Text] [Related]
19. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.
Fiorucci S; Baldoni M; Ricci P; Zampella A; Distrutti E; Biagioli M
Curr Opin Pharmacol; 2020 Aug; 53():45-54. PubMed ID: 32480317
[TBL] [Abstract][Full Text] [Related]
20. Bile acids and their receptors in metabolic disorders.
Fiorucci S; Distrutti E; Carino A; Zampella A; Biagioli M
Prog Lipid Res; 2021 Apr; 82():101094. PubMed ID: 33636214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
